TamirBio

Tamir Biotechnology, Inc. is a biopharmaceutical company primarily engaged in the discovery and development of therapeutic drugs for treating cancer and other pathological conditions. Its patented drug discovery and development programs include therapeutics derived from amphibian ribonucleases. The company's lead candidate drug, ONCONASE, is being evaluated in human clinical trials for the treatment of various forms of cancer. Tamir Biotechnology is also focused on new drug applications for unresectable malignant mesothelioma and has completed a Phase I clinical trial for the treatment of non-small cell lung cancer.